Effect Of CYP2B6 C.516G>T And C.983T>C Single Nucleotide Polymorphisms On Plasma Nevirapine Levels In Zimbabwean HIV/AIDS Patients | 37654
Journal of Molecular and Genetic Medicine
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Given the high prevalence of HIV/AIDS in sub-Saharan Africa, and the elusive search for a cure, understanding the
pharmacogenetics of currently used drugs is critical in populations from the most affected regions. Compared to Asian and
Caucasian populations, African population groups are more genetically diverse, making it difficult to extrapolate findings from
one ethnic group to another. This study aimed to investigate the role of genetic variation in CYP2B6 (c.516G>T and c.983T>C)
single nucleotide polymorphisms on plasma nevirapine levels among HIV-infected adult Zimbabwean patients. Using a crosssectional
study, patients on nevirapine-containing HAART, having reached steady state (more than six weeks on treatment) were
recruited to participate. Blood samples were collected after patients provided consent and samples were used to extract DNA for
genetic analysis or to measure plasma nevirapine levels. Genetic analysis was carried out using PCR and RFLP or SNaPshot for
the two single nucleotide polymorphisms; CYP2B6 c.516G>T and c.983T>C, while LC-MS/MS was used in analysing nevirapine
concentration. CYP2B6 c.516G>T and c.983T>C significantly predicted plasma nevirapine concentration with the c.516T and
c.983T being associated with elevated plasma nevirapine concentrations. Comparisons of the variant allele frequencies observed in
this group to those reported in some African, Caucasian and Asian populations showed significant differences. We conclude that
pharmacogenetics of nevirapine can be creatively used to determine patients who are likely to develop nevirapine-associated side
effects as well as too low plasma concentrations for viral suppression.
Doreen Duri is a 27-year old Biomedical Scientist employed by the University of Zimbabwe in the Department of Chemical Pathology. She completed an Honours Degree in Medical Laboratory Sciences from the University of Zimbabwe in 2012 and is currently a graduate student at the same university. She is a budding researcher actively involved in antiretroviral drugs pharmacogenetics research.